Identification of Epigenetic-Dysregulated lncRNAs Signature in Osteosarcoma by Multi-Omics Data Analysis

被引:5
作者
Huang, Junchao [1 ]
Zhang, Jingwei [1 ]
Xiao, Haijun [1 ]
机构
[1] Anhui Univ Sci & Technol, Fengxian Hosp, Dept Orthoped, Shanghai, Peoples R China
关键词
osteosarcoma; histone modification; long non-coding RNAs; multiomics; prognosis; LONG NONCODING RNA; DNA METHYLATION; CANCER; PROGRESSION;
D O I
10.3389/fmed.2022.892593
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundAlterations of epigenetic modification patterns are potential markers of cancer. The current study characterized six histone modifications in osteosarcoma and identified epigenetically dysregulated long non-coding RNAs (epi-lncRNAs). MethodsMulti-omics data were obtained from osteosarcoma cell line SJSA1 and a normal cell line. Differentially expressed lncRNAs (DElncRNAs) between osteosarcoma and normal skeletal muscle were analyzed using Limma. MACS2 was applied to identify the "peaks" modified by each histone in the cell. Promoters or enhancers of DElncRNA were overlapped with differential histone-modified regions (DHMR) to screen epi-lncRNAs. Univariate and multivariate Cox regression analysis were performed to detect the genes closely related to the prognosis of osteosarcoma and to construct risk models. ResultsA total of 17 symbolic epi-lncRNA in osteosarcoma were screened, and 13 of them were differentially expressed between osteosarcoma and normal samples. Eight epi-lncRNAs were retained by Univariate Cox regression analysis. Four of these epi-lncRNAs were used to construct an epi-lncRNA signature. The risk score of each osteosarcoma sample in the high- or low-risk group was estimated according to the epi-lncRNA signature. The overall survival (OS) of the low-risk group was significantly better than that of the high-risk group. The area under the receiver operating characteristic (ROC) curve of the model was 0.79 and 0.82 for 1-, 3-, and 5-year OS, respectively. ConclusionOur results revealed the histone modification pattern in osteosarcoma and developed 4-epi-lncRNA signature to predict the prognosis of osteosarcoma, laying a foundation for the identification of highly specific epigenetic biomarkers for osteosarcoma.
引用
收藏
页数:12
相关论文
共 40 条
[11]   Epigenetic mechanisms in breast cancer therapy and resistance [J].
Garcia-Martinez, Liliana ;
Zhang, Yusheng ;
Nakata, Yuichiro ;
Chan, Ho Lam ;
Morey, Lluis .
NATURE COMMUNICATIONS, 2021, 12 (01)
[12]   GSVA: gene set variation analysis for microarray and RNA-Seq data [J].
Haenzelmann, Sonja ;
Castelo, Robert ;
Guinney, Justin .
BMC BIOINFORMATICS, 2013, 14
[13]   Interplay between long non-coding RNAs and epigenetic machinery: emerging targets in cancer? [J].
Hanly, David J. ;
Esteller, Manel ;
Berdasco, Maria .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2018, 373 (1748)
[14]   Histones and histone modifications in perinuclear chromatin anchoring: from yeast to man [J].
Harr, Jennifer C. ;
Gonzalez-Sandoval, Adriana ;
Gasser, Susan M. .
EMBO REPORTS, 2016, 17 (02) :139-155
[15]   LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis [J].
He, Wenlong ;
Zhang, Yeying ;
Xia, Shulan .
THORACIC CANCER, 2020, 11 (03) :549-560
[16]   Translational biology of osteosarcoma [J].
Kansara, Maya ;
Teng, Michele W. ;
Smyth, Mark J. ;
Thomas, David M. .
NATURE REVIEWS CANCER, 2014, 14 (11) :722-735
[17]   Identification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data Analysis [J].
Kikutake, Chie ;
Yahara, Koji .
PLOS ONE, 2016, 11 (04)
[18]   WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs [J].
Liao, Yuxing ;
Wang, Jing ;
Jaehnig, Eric J. ;
Shi, Zhiao ;
Zhang, Bing .
NUCLEIC ACIDS RESEARCH, 2019, 47 (W1) :W199-W205
[19]   DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma [J].
Lu, Chenfei ;
Wei, Yutian ;
Wang, Xiefeng ;
Zhang, Zhuoran ;
Yin, Jianxing ;
Li, Wentao ;
Chen, Lijiu ;
Lyu, Xiao ;
Shi, Zhumei ;
Yan, Wei ;
You, Yongping .
MOLECULAR CANCER, 2020, 19 (01)
[20]   Resource-appropriate selection of osteosarcoma treatment protocols in low- and middle-income countries [J].
Mailankody, Sharada ;
Kumar, Venkatesan Sampath ;
Khan, Shah Alam ;
Banavali, Shripad D. ;
Bajpai, Jyoti .
PEDIATRIC BLOOD & CANCER, 2022, 69 (03)